Blog
RSS FeedPosted by Michael Wonder on 22 Sep 2019
A new deal protects Australians chemists at the expense of patients
22 September 2019 - Australia’s 3000 pharmacy owners have a government guaranteed monopoly that is pushing up medicine prices and the ...
Posted by Michael Wonder on 20 Sep 2019
Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer
19 September 2019 - Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer. ...
Posted by Michael Wonder on 19 Sep 2019
National pharmacare cheaper than healing people who can't afford their drugs
17 September 2019 - A national pharmacare program could potentially reduce prescription drug spending by aggregating the buying power of all ...
Posted by Michael Wonder on 19 Sep 2019
5 people setting EU drug prices
19 September 2019 - Politic’s guide to the policy makers debating how to calculate the cost of cures. ...
Posted by Michael Wonder on 19 Sep 2019
Electronic prescribing
19 September 2019 - Electronic Prescribing will provide an option for prescribers (including doctors, dentists, optometrists, midwives and nurse practitioners), and ...
Posted by Michael Wonder on 18 Sep 2019
Xanax still being overprescribed despite policy changes
19 September 2019 - Patients are still being prescribed hundreds of Xanax tablets a year despite a cut in government ...
Posted by Michael Wonder on 18 Sep 2019
Health technology agency insights: informing modification of a qualitative benefit risk framework for health technology reassessment of prescription medications
16 September 2019 - This study's intent was to determine if a qualitative benefit risk framework could be used or modified ...
Posted by Michael Wonder on 18 Sep 2019
Three-year-old Matilda's ability to walk is giving hope to those with spinal muscular atrophy
18 September 2019 - The disease, which has been described as motor neurone disease for children, is the leading cause of ...
Posted by Michael Wonder on 18 Sep 2019
NICE recommends Takhzyro
18 September 2019 - NICE - a health technology appraisal body in England and Wales - has recommended the use ...
Posted by Michael Wonder on 18 Sep 2019
'A child's health should not be a postcode lottery': anger of cystic fibrosis sufferers forced to pay £20,000 for drug abroad
17 September 2019 - Patients have formed a buyers' club to source a version of Orkambi after the drug's manufacturer and ...
Posted by Michael Wonder on 17 Sep 2019
News NHS England explores funding options for cystic fibrosis drug
17 September 2019 - NHS England is “committed to exploring and developing alternative routes” to enable people with cystic fibrosis ...
Posted by Michael Wonder on 17 Sep 2019
PHARMAC may have to compete for measles vaccine
17 September 2019 - PHARMAC is looking at whether it can order more measles vaccine in case the latest batch runs ...
Posted by Michael Wonder on 16 Sep 2019
HTA in the European Union: osteoporosis screening without proof of benefit
16 September 2019 - For the first time, an IQWiG team is in charge of assessing health technology for the ...
Posted by Michael Wonder on 16 Sep 2019
Canada decides: Leading parties plan to tackle ways to make medicine affordable
16 September 2019 - Canadian voters will be hearing a lot about a new national prescription drug program to fill a ...
Posted by Michael Wonder on 13 Sep 2019
Vertex announces new access agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)
12 September 2019 - Eligible patients in Scotland will immediately have access to Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) in combination with ...